In  light of the growing concern over recent Avian Influenza outbreaks in China, Protein Sciences Corporation, maker of the highly effective Flublok® Influenza Vaccine, reports that the Biomedical Advanced Research and Development Authority (BARDA) has requested the development of two new pandemic vaccine candidates to combat new H7N9 strains, one representing a pathogenic H7N9 virus.